IP Library Granted Patent US 7,534,613
Granted Patent B2
US 7,534,613 · App. 11/102,521 · Granted May 19, 2009

Methods of treating parkinson's disease using viral vectors

Assignees: Genzyme Corporation; The Regents of the University of California
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,534,613
App. No.
11/102,521
Granted
May 19, 2009
Kind
B2
Abstract

Methods of delivering viral vectors, particularly recombinant AAV virions, to the CNS are provided. Also provided are methods of treating Parkinson's Disease.

Claims (39)

1. A method of delivering recombinant adeno-associated virus virions to the brain of a primate, said method comprising:

(a) providing a composition comprising at least 2.5x10 9 recombinant adeno-associated virus virions, wherein said recombinant adeno-associated virus virions comprise a recombinant nucleotide sequence of interest that encodes a protein; and

(b) administering said composition to said brain using a non-manual pump such that distribution of said recombinant adeno-associated virus virions over an area greater than 5 mm 2 is achieved.

2. The method of claim 1 , wherein the composition provided in (a) comprises at least 2.5x10 10 recombinant adeno-associated virus virions.

3. The method of claim 1 , wherein said protein is aromatic amino acid decarboxylase (AADC).

4. The method of claim 1 , wherein said pump is an infusion pump or an osmotic pump.

5. The method of claim 1 , wherein said composition is administered to striatum of the brain.

6. The method of claim 1 , wherein said composition is administered under a pressure gradient.

7. The method of claim 1 , wherein said method further comprising administering oral L-dopa to said primate.

8. The method of claim 1 , wherein said primate suffers from a central nervous system (CNS) disorder.

9. The method of claim 8 , wherein said CNS disorder is Parkinson's disease.

10. A method of delivering recombinant adeno-associated virus virions to the brain of a primate, said method comprising:

(a) providing a composition comprising at least 2.5x10 10 recombinant adeno-associated virus virions, wherein said recombinant adeno-associated virus virions comprise a recombinant nucleotide sequence of interest that encodes a protein; and

(b) administering said composition to said brain using a non-manual pump such that distribution of said recombinant adeno-associated virus virions over a volume of at least 250mm 3 is achieved.

11. The method of claim 10 , wherein said protein is aromatic amino acid decarboxylase (AADC).

12. The method of claim 10 , wherein said pump is an infusion pump or an osmotic pump.

13. The method of claim 10 , wherein said composition is administered to striatum of the brain.

14. The method of claim 10 , wherein said composition is administered under a pressure gradient.

15. The method of claim 10 , wherein said method further comprising administering oral L-dopa to said primate.

16. The method of claim 10 , wherein said primate suffers from a central nervous system (CNS) disorder.

17. The method of claim 16 wherein said CNS disorder is Parkinson's disease.

18. A method of delivering recombinant adeno-associated virus virions over an area of the central nervous system (CNS) of a primate, said method comprising:

(a) providing a composition comprising at least 2.5x10 10 recombinant adeno-associated virus virions, wherein said recombinant virions comprise a recombinant nucleotide sequence of interest that encodes a protein; and

(b) administering said composition to the CNS of the primate such that distribution of said recombinant virions over an area greater than 5 mm 2 or over a volume of at least 250 mm 3 is achieved, wherein said composition is administered by convention-enhanced delivery using a non-manual pump.

19. The method of claim 18 , wherein said protein is aromatic amino acid decarboxylase (AADC).

20. The method of claim 18 , wherein said pump is an infusion pump or an osmotic pump.

21. The method of claim 18 , wherein said composition is administered to striatum of the brain.

22. The method of claim 18 , wherein said composition is administered under a pressure gradient.

23. The method of claim 18 , wherein said method further comprising administering oral L-dopa to said primate.

24. The method of claim 18 , wherein said CNS disorder is Parkinson's disease.

25. A method of delivering recombinant adeno-associated virus virions to the brain of a primate suffering from Parkinson's disease, said method comprising:

(a) providing a composition comprising at least 2.5x10 10 recombinant adeno-associated virus virions, wherein said recombinant adeno-associated virus virions encode aromatic amino acid decarboxylase (AADC);

(b) orally administering L-dopa to said primate; and

(c) administering said composition to striatum of said primate using an infusion pump such that distribution of said recombinant adeno-associated virus virions over an area greater than 5 mm 2 or over a volume of at least 250 mm 3 is achieved.

26. The method of claim 25 , wherein said composition is administered under a pressure gradient.

27. A method of delivering recombinant adeno-associated virus virions to the striatum of the brain of a primate, said method comprising:

(a) providing a composition comprising at least 2.5x10 10 recombinant adeno-associated virus virions, wherein said recombinant adeno-associated virus virions comprise a recombinant nucleotide sequence of interest that encodes a protein; and

(b) administering said composition to said brain using an infusion pump or an osmotic pump such that distribution of said recombinant adeno-associated virus virions over an area greater than 5 mm 2 or over a volume of at least 250 mm 3 is achieved.

28. The method of claim 27 , wherein said composition is administered under a pressure gradient.

Assignments (2)
CONFIRMATORY LICENSE Recorded Feb 19, 2008
From: CALIFORNIA, THE REGENTS OF THE UNIVERSITY OF
To: ENERGY, UNITED STATES DEPARTMENT OF
Reel/Frame 020529/0954 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 25, 2007
From: AVIGEN, INC.
To: GENZYME CORPORATION
Reel/Frame 020010/0563 →
Continuity (5)
Continuation 0988785400 · Jun 21, 2001
Continuation 0932017100 · May 26, 1999
Provisional Application 6013474800 · May 18, 1999
Provisional Application 6008694900 · May 27, 1998
Related Publication 20050180955A1 · Aug 18, 2005